StockData
Immuron Ltd logo

Immuron Ltd (IMRN) company profile

IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Sep 24, 2026Score 4/30
$0.87−0.03 (-3.20%)

Close on Nov 17, 2026Market cap $7.03MP/E –Yield –

About Immuron

Pharmaceutical Preparations, SIC 2834

Immuron Limited is an Australian biopharmaceutical company engaged in developing and commercializing orally delivered polyclonal antibody therapies targeting mucosal surfaces in the gastrointestinal tract. The company focuses on addressing conditions such as travelers' diarrhea, irritable bowel syndrome, and enteric infections caused by pathogens like Enterotoxigenic Escherichia coli and Clostridioides difficile. Its commercial offerings include Travelan, an over-the-counter formulation designed to lower the incidence of travelers' diarrhea, and ProIBS, an orally administered product containing AVH200 that creates a protective hydrogel barrier to soothe irritable bowel syndrome symptoms. Operating across hyper-immune products and research and development divisions, the business primarily supplies retail consumers and travel health markets through retail pharmacies, clinical practitioners, and online channels.

Headquartered in Carlton South, Victoria, Australia, Immuron markets its commercial products across several international jurisdictions. The enterprise distributes Travelan through pharmacies throughout Australia, sells the product as a licensed natural health item in Canada, and distributes it as a dietary supplement within the United States. ProIBS is marketed to patients and consumers in Australia.

Summary of the business section of Immuron's latest annual report, written by StockData.

Company profile

Company

Legal name
Immuron Ltd
Founded
1994
Headquarters
Carlton, Victoria, C3
Address
62 Lygon Street, Level 3 3053
Phone
61 03 9824 5254
Employees
7, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
C3
Fiscal year ends
June 30
Auditor
GRANT THORNTON AUDIT PTY LTD, Melbourne, Victoria

Stock & identifiers

Ticker
IMRN
Exchange
Nasdaq
IPO date
Jun 12, 2017
Shares outstanding
323M, Jun 30, 2026
Filer category
Non-accelerated filer
SEC CIK
1660046
CUSIP
45254U101
ISIN
US45254U1016
FIGI
BBG000LZD9X8
Share class FIGI
BBG001T0C840
LEI
529900ZIDI5C9C9TTI91
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul Gerard BrennanChairman of the Board, Director–
Flavio PalumboChief Commercial Officer1,142,909
Steven George LydeamoreChief Executive Officer3,155,047
Aaron James LauritaChief Financial Officer–
Jerry KanellosChief Scientific Officer333,000
Daniel Jude PollockDirector743,230
Jeannette Anne JoughinDirector–
Ravi SavarirayanDirector877,840

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 12, 2017
Offer price
$9.99
Securities offered
610,000
Gross proceeds
$6.09M
Exchange
Nasdaq
Lock-up ends (est.)
Dec 9, 2017

“Per ADS Per Warrant Total Public offering price $ 9.99 $ 0.01 $ 10.00 Underwriting discounts and commissions (1) $ 0.6993 $ 0.0007 $ 0.70 Proceeds, before expenses, to us $ 9.207 $ 0.0093 $ 9.30 (1) Does not include a non-accountable expense allowance equal to 1% of the gross proceeds of this offering payable to Joseph Gunna”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had seven full-time employees and one part time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?